A Phase 2 interventional study of Placebo and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-07-29.
Sponsored by Takeda · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.
Among the 29 studies testing febuxostat in Gout, this one is the 13th largest by enrollment, is one of 2 that started in 2001, is one of 9 in phase 2, and was the 2nd registered.
347 studies on the registry are indexed under Gout; 50 are open to participants now.
Browse Gout studies →1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:
Haiphong University of Medicine and Pharmacy
Healthy volunteers
Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 83 across 288 interventional studies indexed under Gout.
Median enrollment 109 across the 29 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 29 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Gout by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Gout by Takeda, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2001, is one of 5 in phase 2, and was the 2nd registered.
Takeda’s Gout studies by the year they started, since 2001.
1 of the studies testing febuxostat in Gout that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07369622Haiphong University of Medicine and PharmacyHLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing febuxostat in Gout, from their registry updates:
Among Takeda’s 15 in Gout:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout.
Gout is a chronic urate crystal deposition disorder, which if left untreated may result in progressive disease characterized by joint and bone destruction from tophaceous deposits and renal impairment due to gouty nephropathy. Hyperuricemia, defined as a serum urate concentration of >7.0 milligrams per deciliter (mg/dL), is the underlying metabolic aberration leading to urate crystal deposition in gout. Gout has several clinical presentations, including: recurrent acute attacks of inflammatory arthritis; deposition of monosodium urate monohydrate crystals in joints, bones and even parenchymal organs (tophaceous gout); renal impairment; and uric acid nephrolithiasis. As serum urate levels increase beyond >7.0 mg/dL, the risks for gouty arthritis or for renal calculi increase.
Currently allopurinol is the only xanthine oxidase inhibitor available. Allopurinol is the agent of choice for reduction of serum urate levels in patients with: uric acid overproduction; unresponsive or intolerant to uricosuric agents; impaired renal function; uric acid urolithiasis; or tophi.
Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Febuxostat
Drug: Febuxostat
Drug: Febuxostat
Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
Also known as: TMX-67, Tei-6720, Uloric
Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
Also known as: TMX-67, Tei-6720, Uloric
Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
Also known as: TMX-67, Tei-6720, Uloric
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.
Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 28 visit was summarized.
Time frame: Day 28.
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.
Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 7 visit was summarized.
Time frame: Day 7.
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.
Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 14 visit was summarized.
Time frame: Day 14.
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.
Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 21 visit was summarized.
Time frame: Day 21.
Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.
Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.
Time frame: Baseline and Day 7.
Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.
Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.
Time frame: Baseline and Day 14.
Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit
Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.
Time frame: Baseline and Day 21.
Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.
Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.
Time frame: Baseline and Day 28.
Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.
Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.
Time frame: Baseline and Any visit (Day 7, 14, 21,or 28)
Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.
24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.
Time frame: Baseline and Day 28.
Subjects were enrolled at 24 investigative sites from 31 January 2001 to 9 July 2001
| Milestone | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Started | 37 | 40 | 38 | 38 |
| Completed | 36 | 37 | 36 | 36 |
| Not completed | 1 | 3 | 2 | 2 |
| Withdrew: Adverse event | 1 | 2 | 2 | 1 |
| Withdrew: Gout flare | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 28 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit. | 56 | 76 | 94 | 0 |
Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 7 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit. | 50 | 59 | 91 | 3 |
Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 14 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit. | 56 | 68 | 94 | 0 |
Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 21 visit was summarized.
| percentage of subjects | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit. | 59 | 76 | 97 | 0 |
Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit. | -35.0 ± 9.67 | -39.2 ± 15.9 | -53.44 ± 12.3 | 0.71 ± 12.6 |
Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit. | -37.1 ± 11.70 | -41.8 ± 14.63 | -56.9 ± 8.36 | 1.62 ± 10.21 |
Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit | -37.3 ± 11.30 | -43.9 ± 16.3 | -59.4 ± 7.58 | -0.57 ± 10.63 |
Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit. | -36.6 ± 12.07 | -44.3 ± 17.53 | -59.1 ± 9.92 | -2.2 ± 12.5 |
Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period. | 42.5 ± 10.04 | 49.2 ± 13.24 | 62.8 ± 7.05 | 10.0 ± 11.12 |
24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.
| percent change from baseline | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28. | -43.6 ± 28.9 | -46.5 ± 27.0 | -45.7 ± 30.1 | 5.9 ± 37.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat 40 mg QD | — | 0/37 (0%) | 18/37 (48.6%) |
| Febuxostat 80 mg QD | — | 1/40 (2.5%) | 19/40 (47.5%) |
| Febuxostat 120 mg QD | — | 2/38 (5.3%) | 16/38 (42.1%) |
| Placebo QD | — | 0/38 (0%) | 17/38 (44.7%) |
| Event | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| Suicide AttemptPsychiatric disorders | 0/37 | 0/40 | 1/38 | 0/38 |
| Back PainGeneral disorders | 0/37 | 0/40 | 1/38 | 0/38 |
| DeliriumNervous system disorders | 0/37 | 1/40 | 0/38 | 0/38 |
| Guillian Barre SyndromeNervous system disorders | 0/37 | 1/40 | 0/38 | 0/38 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/37 | 1/40 | 0/38 | 0/38 |
| Event | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/37 | 8/40 | 4/38 | 4/38 |
| PainGeneral disorders | 6/37 | 3/40 | 2/38 | 4/38 |
| Back PainGeneral disorders | 3/37 | 2/40 | 2/38 | 1/38 |
| HeadacheNervous system disorders | 3/37 | 2/40 | 2/38 | 1/38 |
| Abdominal PainGeneral disorders | 1/37 | 1/40 | 2/38 | 3/38 |
| RashSkin and subcutaneous tissue disorders | 0/37 | 1/40 | 3/38 | 0/38 |
| Increased AppetiteGastrointestinal disorders | 2/37 | 0/40 | 0/38 | 0/38 |
| Liver Function Tests AbnormalInvestigations | 2/37 | 1/40 | 1/38 | 1/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/37 | 1/40 | 2/38 | 0/38 |
| Flu SyndromeGeneral disorders | 1/37 | 0/40 | 1/38 | 2/38 |
| Age Continuous(years) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD | Total |
|---|---|---|---|---|---|
| Mean | 52.2 ± 14.04 | 55.2 ± 13.09 | 56.2 ± 10.83 | 52.4 ± 12.63 | 54.0 ± 12.69 |
| Age, Customized(participants) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD | Total |
|---|---|---|---|---|---|
| <45 years | 8 | 10 | 7 | 12 | 37 |
| 45 years to <65 years | 21 | 19 | 23 | 17 | 80 |
| ≥65 years | 8 | 11 | 8 | 9 | 36 |
| Sex: Female, Male(Participants) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD | Total |
|---|---|---|---|---|---|
| Female | 4 | 2 | 5 | 6 | 17 |
| Male | 33 | 38 | 33 | 32 | 136 |
| Race/Ethnicity, Customized(participants) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD | Total |
|---|---|---|---|---|---|
| White | 32 | 35 | 34 | 32 | 133 |
| Black or African American | 3 | 3 | 2 | 3 | 11 |
| Hispanic | 1 | 1 | 1 | 1 | 4 |
| Asian | 0 | 1 | 1 | 0 | 2 |
| Other | 1 | 0 | 0 | 2 | 3 |
| Body Mass Index(participants) | Febuxostat 40 mg QD | Febuxostat 80 mg QD | Febuxostat 120 mg QD | Placebo QD | Total |
|---|---|---|---|---|---|
| ≤25 kilogram per meter² (kg/m²) | 2 | 3 | 3 | 0 | 8 |
| >25 kg/m² to 30 kg/m² | 12 | 12 | 14 | 13 | 51 |
| >30 kg/m² to 35 kg/m² | 16 | 12 | 12 | 16 | 56 |
| >35 kg/m² to 40 kg/m² | 4 | 7 | 5 | 6 | 22 |
| >40 kg/m² | 3 | 6 | 3 | 3 | 15 |
| missing | 0 | 0 | 1 | 0 | 1 |
No study locations are listed for this record.
The record gives a start of Jan 2001, a primary completion of Jul 2001 and a completion of Jul 2001. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 8 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat